Month 12 on Semaglutide: One Year In
Fifty-two weeks. Roughly fifty injections. A full calendar year on semaglutide is a real milestone, and it is the place where most of the major trial data measures its primary endpoint. Time to take stock of where you actually landed.
In the STEP 1 trial of semaglutide 2.4mg for chronic weight management, mean weight loss at week 68 was approximately 14.9% from baseline, compared with 2.4% on placebo. That is the headline number you have probably seen quoted. The 52-week mark (one year) sits very close to that — most users by this point are within a couple of percentage points of where they will plateau.
Real-world results vary more than trial results. Some people land well above 15% at one year; many sit in the 10–15% range; some are in the single digits. The factors that explain the spread are familiar: starting weight, titration pace, adherence, sleep, protein intake, resistance training, and life-circumstance shocks during the year.
Appetite Suppression
Stable, predictable suppression. The medication-related effort has long since dropped to near zero — the routine runs on autopilot for most users.
Mean cumulative loss at 68 weeks in STEP 1 was 14.9%. Most one-year users sit close to that, with the curve nearly flat by this stage.
The Month 12 journey
The Month 12 Timeline
Weeks 45-46
Steady at Maintenance
Most users have been at 2.4mg for several months. Weekly injections are routine, side effects are minimal or absent, and the body's response is fully known.
Weeks 47-48
Annual Review
Full lab panel, body composition if available, blood pressure, and a structured review of the year's data. Many prescribers also reassess for bone density and lean mass at this point.
End of Month 12
Year Two Decision
Continue at 2.4mg for ongoing weight management, hold at a lower dose, or — less commonly — taper. Trial data supports continued use for sustained weight maintenance; stopping is associated with substantial regain.
What changes by Month 12
A year of consistent treatment usually produces visible body composition change beyond the scale. Waist circumference, fitness markers, and inflammatory labs typically improve more than weight alone would predict. Many users report metabolic markers (A1C, fasting glucose, triglycerides, LDL) that look meaningfully different from baseline. For some, comorbidities tracked at diagnosis — high blood pressure, prediabetes, sleep apnea — have improved or resolved.
The maintenance question is the central one at year one. Trial data, particularly the STEP 4 withdrawal study, shows that stopping semaglutide is associated with substantial weight regain — about two-thirds of the lost weight returns within a year off the medication. For most users on it long-term, the framing has shifted: this is a chronic condition treatment, not a finite course.
The habit picture matters more at month 12 than at any earlier point. A year of practice has either built durable patterns or revealed gaps that lighter doses, off-medication periods, or stress events will expose. Most users describe a kind of practiced calm around food that did not exist a year earlier — that is the part that, ideally, persists regardless of what happens with the dose.
Navigating Symptoms
Long-term safety data through two years in STEP trials remains favorable. New severe abdominal pain, persistent vomiting, or vision changes should still prompt evaluation, even after a year of stable use.
What other users say
What Users Report
“One year, down 16%, A1C normal, blood pressure off two of three meds. I plan to stay on 2.4mg indefinitely. The cost is real but so is the trade.”
— Naomi K.
“I landed at about 12%. Less than I hoped, more than I have ever sustained. My doctor and I are continuing as-is into year two.”
— Ethan G.
Looking ahead
Year two is mostly a maintenance story. The conversation moves from active loss to sustaining the result — and, for some, deciding whether and how to step down. Visit the resources hub for guides on plateaus, long-term dosing, and what comes after the one-year mark.